Zai Lab Ltd (ZLAB): Capital Expenditures
$8.10M
Year ended 2025-12-31
$6.19M
Trailing 12 months to 2026-06-30
-30.9%
3-year compound annual growth
-4.4%
5-year compound annual growth
+27.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.10M | +43.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $5.66M | -21.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $7.21M | -70.7% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $24.59M | +34.4% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $18.30M | +80.6% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $10.13M | +67.9% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $6.04M | -39.7% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $10.02M | +10.0% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $9.10M | +309.3% | 2020-04-29, From 2017-01-01 |
| 2016-12-31 | $2.22M | +201.1% | 2019-03-29, From 2016-01-01 |
| 2015-12-31 | $738.5K | n/a | 2018-04-30, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $8.10M | +43.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $1.10M | +17.6% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.13M | +318.9% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $1.49M | +47.6% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $954.0K | -3.9% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $48.92M | -49.0% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $14.15M | -21.1% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $686.0K | +379.7% |
Compare ZLAB, NATR, BBIO, INVA side by side · Screen every company in Pharmaceutical Preparations ↗